In addition, personalized treatment is widely integrated with AML treatment strategies, depending on mutational status; for example, the FLT3 inhibitor midostaurin combined with intensive induction and consolidation chemotherapy followed by a 1-year maintenance therapy yielded significantly better survival outcomes of patients with FLT3-mutated AML [7, 8]. This evidence concerns the gene FLT3 and acute myeloid leukemia.